Lenacapavir: A Promising HIV Prevention Breakthrough and its Global Accessibility Challenges
Lenacapavir: A Promising HIV Prevention Breakthrough and its Global Accessibility Challenges The recent FDA approval of lenacapavir marks a significant advancement in HIV prevention. This long-acting injectable drug, administered just twice yearly, offers a compelling alternative to daily oral PrEP (pre-exposure prophylaxis) medications like Truvada. Clinical trials, including PURPOSE 1 and PURPOSE 2, demonstrated remarkably high efficacy rates, approaching near-complete protection against HIV infection in diverse populations. These results, hailed as a “Breakthrough of the Year” by Science in 2024,…